Mabwell (Shanghai) Bioscience マネジメント

マネジメント基準チェック /24

Mabwell (Shanghai) Bioscienceの CEO はDatao Liuで、 Jun2020年に任命され、の在任期間は 4.42年です。は、会社の株式の3.78%を直接所有しており、その価値はCN¥ 366.18M 。経営陣と取締役会の平均在任期間はそれぞれ4.4年と4.4年です。

主要情報

Datao Liu

最高経営責任者

CN¥2.4m

報酬総額

CEO給与比率	n/a
CEO在任期間	4.4yrs
CEOの所有権	3.8%
経営陣の平均在職期間	4.4yrs
取締役会の平均在任期間	4.4yrs

経営陣の近況

Recent updates

Mabwell (Shanghai) Bioscience (SHSE:688062) Has Debt But No Earnings; Should You Worry?

Aug 19

CEO（最高経営責任者

Datao Liu (52 yo)

4.4yrs

在職期間

CN¥2,406,000

報酬

Dr. Datao Liu serves as the General Manager and Director of Mabwell (Shanghai) Bioscience Co., Ltd. since June 2020 and serves as it Chief Executive Officer and has been its Chairman since June 2023. He al...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Datao Liu	Chairman	4.4yrs	CN¥2.41m	3.78% CN¥ 366.2m
Xin Du	Chief Scientific Officer & President of Maiwei (US)	4.4yrs	CN¥3.14m	データなし
Yinhan Guo	Chief R&D Officer	4.1yrs	CN¥1.93m	データなし
Jinchao Zhang	Deputy General Manager	4.4yrs	CN¥1.59m	1% CN¥ 97.0m
Huiguo Hu	Deputy GM	4.4yrs	CN¥1.58m	データなし
Shu Hai Wang	Deputy General Manager	4.4yrs	CN¥1.58m	0.10% CN¥ 9.7m
Xi Chen	Deputy General Manager	3.8yrs	CN¥1.58m	データなし
Han Li	Deputy General Manager	4.2yrs	CN¥1.94m	データなし
Weiyi Dong	Deputy General Manager	4.4yrs	CN¥961.20k	データなし
Hua Ni	Deputy General Manager	4.2yrs	CN¥1.42m	データなし
Hai Wu	President of R&D	less than a year	データなし	データなし

4.4yrs

平均在職期間

52yo

平均年齢

経験豊富な経営陣: 688062の経営陣は経験豊富であると考えられます ( 4.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Datao Liu	Chairman	4.4yrs	CN¥2.41m	3.78% CN¥ 366.2m
Huiguo Hu	Deputy GM	3.5yrs	CN¥1.58m	データなし
Chunshan Tang	Director	4.4yrs	データなし	35.18% CN¥ 3.4b
Ning Xie	Director	4.4yrs	CN¥1.55m	1.64% CN¥ 159.3m
Bailing Li	Independent Director	4.1yrs	CN¥180.00k	データなし
Qian Zhao	Independent Director	4.1yrs	CN¥180.00k	データなし
Qing Xu	Independent Director	4.1yrs	CN¥180.00k	データなし
Yongqi Guo	Director	4.4yrs	データなし	データなし
Jian Chu	Chairman of the Supervisory Board	4.4yrs	データなし	データなし
Xianghong Huang	Employee Representative Supervisor	4.4yrs	データなし	データなし
Yue Yin	Supervisor	4.4yrs	データなし	データなし

4.4yrs

平均在職期間

53yo

平均年齢

経験豊富なボード: 688062の取締役会は経験豊富であると考えられます ( 4.4年の平均在任期間)。

Mabwell (Shanghai) Bioscience マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Mabwell (Shanghai) Bioscience Co., Ltd., Annual General Meeting, Apr 29, 2024

Insufficient new directors

High number of new and inexperienced directors

Recent updates

Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Approved for 2 Clinical Trials by CDE of NMPA

New major risk - Share price stability

Mabwell (Shanghai) Bioscience Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer

Mabwell (Shanghai) Bioscience (SHSE:688062) Has Debt But No Earnings; Should You Worry?

Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China's NMPA

New minor risk - Share price stability

FDA Grants Orphan Drug Designation to 7MW3711

FDA Grants Fast Track Designation to Mabwell's 9MW2821 for the Treatment of Patients with Locally Advanced or Metastatic Nectin-4 Positive TNBC

Mabwell (Shanghai) Bioscience Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Mabwell Announces 9MW2821 Clinical Data

Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer

Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821

First quarter 2024 earnings released: CN¥0.51 loss per share (vs CN¥0.60 loss in 1Q 2023)

Price target increased by 8.5% to CN¥35.92

Full year 2023 earnings: EPS and revenues miss analyst expectations

Mabwell (Shanghai) Bioscience Co., Ltd., Annual General Meeting, Apr 29, 2024

Mabwell (Shanghai) Bioscience Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Mabwell Presents Clinical Study Data of the 9MW2821 for Patients with Cervical Cancer as Focused Plenary Oral Presentation At the Society of Gynecologic Oncology Annual Meeting

Mabwell Publishes Phase III Study Results of Denosumab Biosimilar in the International Top Journal of Jama Oncology

Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7Mw3711

Mabwell (Shanghai) Bioscience Co., Ltd. to Report Fiscal Year 2023 Results on Apr 09, 2024

National Medical Products Administration Accepts Mabwell's 8MW0511 for Injection Accepted by NMPA

Mabwell Announces the Cde Approval of Novel Nectin-4 Targeting Adc for Phase III Clinical Trial

Insufficient new directors

New major risk - Financial position

Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs

Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor

New major risk - Financial position

Second quarter 2023 earnings released: CN¥0.43 loss per share (vs CN¥0.51 loss in 2Q 2022)

Mabwell (Shanghai) Bioscience Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Mabwell (Shanghai) Bioscience Co., Ltd. Announces the U.S. FDA approval of 9MW3811 for IND

Full year 2022 earnings released: CN¥2.44 loss per share (vs CN¥2.57 loss in FY 2021)

Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND

High number of new and inexperienced directors

Third quarter 2022 earnings released: CN¥0.67 loss per share (vs CN¥0.58 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.51 loss per share (vs CN¥0.58 loss in 2Q 2021)

First quarter 2022 earnings released: CN¥0.55 loss per share (vs CN¥0.61 loss in 1Q 2021)

Full year 2021 earnings released: CN¥2.57 loss per share (vs CN¥2.26 loss in FY 2020)

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24